The drugmaker incurred debt when it acquired Shire, a U.K.-based drugmaker, in 2019, and the sale of its nonprescription drug division is intended to relieve some of that debt.
Takeda will focus its management resources on developing prescription drugs, the company told the Nikkei Asian Review. It plans to sell a total of $10 billion in assets.
Read the full article here.
More articles on pharmacy:
FDA halts approval of blood plasma as COVID-19 treatment
J&J to acquire Momenta Pharma for $6.5B
US sues Teva for alleged MS drug kickback scheme
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
